CK 301

Drug Profile

CK 301

Alternative Names: CK-301

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dana-Farber Cancer Institute
  • Developer Checkpoint Therapeutics
  • Class Antibodies; Antineoplastics
  • Mechanism of Action CD274 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 05 Oct 2017 TG Therapeutics plans clinical trials for B-cell lymphoma
  • 05 Oct 2017 Phase-I clinical trials in Cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Recurrent) in New Zealand (IV) (NCT03212404)
  • 20 Sep 2017 Phase-I clinical trials in Cancer (Late-stage disease, Monotherapy, Recurrent, Metastatic disease, Inoperable/Unresectable) in Australia (IV) (NCT03212404)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top